Inari Medical

Superior clinical evidence and the lowest episode care costs make #ClotTriever the intelligent choice for #DVT thrombectomy. Check out the recent #JVS-VI publication that showed total care costs were $3,400 less with ClotTriever compared to continuous aspiration thrombectomy for #DVT treatment. Learn more: https://bit.ly/3BwW3yh

Today at #TCT2024, Dr. Wissam A Jaber (Co-PI) will take the stage to unveil results from #PEERLESS, a Randomized Controlled Trial (RCT) of #FlowTriever vs. catheter-directed thrombolytics (CDT) in #pulmonaryembolism. Stay tuned! Cardiovascular Research Foundation

#PEERLESS RCT results will be revealed tomorrow at #TCT2024! Stay tuned for what this means for intermediate-risk #pulmonaryembolism patients. Watch the livestream on Oct. 30: https://bit.ly/4h7NZnV #Sponsored by Inari Medical

#TCT2024 is here! We're gearing up for an exciting week in DC as we await results from the #PEERLESS RCT. Be sure to join us all week long. See you there! TCTMD Wissam A Jaber Thomas Tu, MD Jay Giri Samuel Horr, MD Sripal Bangalore

We're just ONE day away from #PEERLESS, a Randomized Controlled Trial (RCT) of FlowTriever vs. catheter-directed thrombolytics (CDT) in #pulmonaryembolism. Don't miss the late-breaking results during #TCT2024 tomorrow! Cardiovascular Research Foundation Wissam A Jaber

We’re live at #TCT2024! Be sure to swing by booth 713 for hands-on demos and to learn more about the upcoming #PEERLESS data release! Cardiovascular Research Foundation

Join us on November 12 as we dive into the results of the #PEERLESS RCT!

ICYMI: We're excited to share that we're partnering with the American Venous Forum | AVF and the National Blood Clot Alliance on #DEFIANCE, a prospective, multinational, randomized controlled trial (“RCT”). The trial will evaluate and compare the clinical outcomes of symptomatic unilateral iliofemoral deep vein thrombosis (DVT) patients following treatment with mechanical thrombectomy using Inari's #ClotTriever System versus anticoagulation alone. We look forward to collaborating in partnership with the American Venous Forum and NBCA as we advance clinical research for #deepveinthrombosis More: https://bit.ly/3Nq8Wg7

We're just 5 days away from #PEERLESS results, a Randomized Controlled Trial (RCT) of FlowTriever vs. catheter-directed thrombolytics (CDT) in #pulmonaryembolism. Don't miss the late-breaking results during #TCT2024! Cardiovascular Research Foundation Wissam A Jaber

Our mission is simple: put #PatientsFirst. With more peer-reviewed data supporting its safety and effectiveness in treating #DVT, #ClotTriever continues to stand out over continuous aspiration vacuum thrombectomy. Let the data do the talking—focus on the facts over flash. #ClotTriever is backed by leading clinical evidence and offers ~$3,400 lower total care costs per episode compared to continuous vacuum aspiration thrombectomy. Learn more: https://bit.ly/3BwW3yh